Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 5/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3331814 | 1.00 | NOS2 (0.37) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL841294 | 1.00 | NOS2 (0.37) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL3331806 | 1.00 | NOS2 (0.37) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL16110335 | 1.00 | NOS2 (0.37) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL16110118 | 1.00 | NOS2 (0.37) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| SCHEMBL879371 | 0.98 | — | — | |
| SCHEMBL249249 | 0.98 | — | — | |
| SCHEMBL15395714 | 0.98 | — | — | |
| SCHEMBL31719935 | 0.91 | NOS2 (0.34) | NOS2NOS1NOS3SLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL18424739 | 0.85 | SLC6A4 (0.38) | NOS2NOS1NOS3CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-20250057850-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4356975-A2 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-04-24 | — | — | EP | disclosed |
| EP-3746424-B1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-11896597-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-02-13 | — | — | US | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11504375-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-11-22 | — | — | US | disclosed |
| CN-111909131-B | ERBB/BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | SLC6A1 3532/4885SLC6A2 4251/4885SLC6A4 4220/4885 |
| US-11896597-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-11007198-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | SLC6A1 4838/4885SLC6A2 4258/4885SLC6A4 4210/4885 |
| US-11504375-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | BCL6, BCL6B, BCL3 | SLC6A1 4616/4885SLC6A2 4536/4885SLC6A4 4678/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
| US-20250057850-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | SLC6A1 3855/4885SLC6A2 4432/4885SLC6A4 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.